8-K: Biomea Fusion Reports Strong Preclinical Weight Loss Data for Oral GLP-1 RA BMF-650 and Sustained Diabetes Remission Potential for Icovamenib

Biomea Fusion, Inc. announced compelling preclinical results for its oral GLP-1 RA candidate BMF-650 in obese non-human primates and durable HbA1c reductions with beta-cell restoration in Type 2 Diabetes patients treated with Icovamenib.

Summary

• Biomea Fusion, Inc. (the Company) reported new preclinical findings for BMF-650, an investigational oral small molecule Glucagon-like peptide-1 receptor agonist (GLP-1 RA) candidate, from a 28-day weight loss study in 15 obese cynomolgus monkeys.
• BMF-650 demonstrated a clear, dose-dependent reduction in daily food intake and pronounced, continuous weight loss over the four-week treatment period, achieving 12% and 15% average weight reduction from baseline at 10 mg/kg and 30 mg/kg doses, respectively.
• These preclinical effects of BMF-650 compared favorably to published data of other leading oral GLP-1 RA candidates in development, showing superior oral bioavailability versus orforglipron across species.
• The Company also provided an update on Icovamenib, its menin inhibitor, from the COVALENT-111 Phase 2a study, highlighting a 1.5% placebo-adjusted HbA1c reduction at Week 26 (p=0.02) in patients with severe insulin-deficient diabetes (SIDD).
• Icovamenib's effect on HbA1c was sustained well beyond the 12-week active treatment period, and it demonstrated a persistent 53% increase in C-peptide levels (indicating insulin secretion) in SIDD patients over 3 months after the final dose.
• Preclinical and clinical data suggest Icovamenib is synergistic with GLP-1 therapies, enhancing insulin secretion and driving quality weight loss with muscle mass preservation in combination studies.
• For the three months ended March 31, 2025, the Company reported a net loss of $29.262 million, with total operating expenses of $29.712 million, and held $36.2 million in cash, cash equivalents, and restricted cash.
• The Company plans an Investigational New Drug (IND) submission for BMF-650 in the second half of 2025, followed by the initiation of a Phase I study in obese healthy volunteers.

Sentiment

Score: 8

Explanation: The document presents highly positive preclinical and early clinical data for two promising drug candidates in large therapeutic areas. The potential for disease modification in diabetes and competitive profile in the GLP-1 space are significant. While the company is currently operating at a loss, the scientific advancements are strong indicators of future potential, warranting a high sentiment score.

Positives

• BMF-650 demonstrated significant and dose-dependent weight reduction (12% at 10 mg/kg, 15% at 30 mg/kg) and reduced food intake in obese non-human primates, comparing favorably to other leading oral GLP-1 RAs.
• BMF-650 showed superior oral bioavailability and a cleaner safety/tolerability profile in preclinical studies compared to orforglipron.
• Icovamenib achieved a statistically significant and clinically meaningful 1.5% placebo-adjusted HbA1c reduction at Week 26 (p=0.02) in severe insulin-deficient diabetes patients, sustained well after the 12-week dosing period.
• Icovamenib demonstrated a persistent 53% increase in C-peptide levels in insulin-deficient patients, indicating restoration of beta-cell function and endogenous insulin production, a potential disease-modifying effect.
• Icovamenib was generally well-tolerated with no clinically significant elevations in aminotransferases or treatment-emergent hypoglycemia.
• Preclinical and early clinical data suggest Icovamenib is synergistic with GLP-1 therapies, showing enhanced insulin secretion and additional benefits in weight loss and muscle mass preservation.
• The Company projects a potential U.S. revenue opportunity of over $6 billion for Icovamenib in Type 2 Diabetes, based on 10% uptake at $10,000 yearly per patient.
• The clinical pathway for Icovamenib may be efficient and cost-effective, with potential for a shorter Phase III program due to its short-term treatment design.

Negatives

• The Company reported a net loss of $29.262 million for the three months ended March 31, 2025.
• Operating expenses totaled $29.712 million for the quarter, indicating a high cash burn rate relative to current cash reserves of $36.2 million.
• Preclinical results, while promising, may not be predictive of future clinical results in humans.
• Cross-study comparisons with other GLP-1 RAs (Ozempic, Mounjaro, Jardiance, Januvia, Orforglipron, CT-996) are inherently limited and may suggest misleading similarities or differences, as no head-to-head trials have been conducted.

Risks

• Results of preclinical studies may not be predictive of future preclinical results or clinical results in connection with planned clinical trials.
• The Company may encounter delays in preclinical or clinical development, interactions with regulatory authorities related to clinical development, and in the initiation, conduct, and completion of planned clinical trials and other research and development activities.
• The Company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those projected.
• Estimates and statistical data relating to market size and growth from independent parties and internal research involve assumptions and limitations, and there is no guarantee as to their accuracy or reliability.

Future Outlook

Biomea Fusion anticipates submitting an Investigational New Drug (IND) application for BMF-650 in the second half of 2025, with a planned initiation of a Phase I study in obese healthy volunteers also in the second half of 2025. The Company expects 52-week follow-up data from its COVALENT-111 and COVALENT-112 studies in the second half of 2025, along with an FDA Type C Meeting update for its Menin Program and planned initiations of Phase IIb (COVALENT-211) and Phase II (COVALENT-212) studies for Icovamenib.

Management Comments

• "We believe we may have a method to reverse diabetes, to reset the body, so diabetes patients no longer require ongoing medication."
• "Icovamenib's recent data has shown an impressive restoration of beta cell function as demonstrated by significant elevations in C-peptide even after the treatment period ended. This data validates the mechanism of action of this menin inhibitor as a disease modifying agent and helps address the poor adherence and persistence commonly seen in type 2 diabetes." Steve Edelman, M.D., Endocrinologist, Professor of Medicine UCSD / VA San Diego
• "The icovamenib data looks exciting. After 26 weeks there have been statistically significant and clinically relevant reductions in HbA1c and excellent tolerability in a prespecified insulin-deficient type 2 diabetes cohort. The data presented today help to confirm icovamenibs mechanism of action. A robust increase in insulin secretion, as measured by C-peptide, was demonstrated 3 months after the icovamenib dosing period and this improvement appears to be continuing. We have not previously seen data like this with any antihyperglycemic agent." Ralph DeFronzo, M. D., Endocrinologist, Professor of Medicine UTHSCSA
• "By addressing insulin-deficient diabetes patients with icovamenib, we have seen post treatment that the beta cell pool is being restored and producing a higher level of insulin, as measured by C-peptide. This indicates a fundamental and potentially lasting impact on the disease and validates the mechanism of action of menin inhibition." Melanie Davies, M.D., Diabetologist, Professor of Diabetes Medicine at the University of Leicester
• "The potential to restore endogenous insulin production capacity is an exciting development in the treatment of type 2 diabetes." Jeremy Pettus, M.D., Endocrinologist, Professor of Medicine UCSD
• "We do not have an agent today that addresses one of the root cause of diabetes beta cell dysfunction icovamenib would be the first. Patients are achieving lasting benefits without continuous chronic dosing, suggesting that icovamenib may be disease modifying." Alice Cheng, M.D., Endocrinologist, Associate Professor of Medicine University of Toronto
• "The Icovamenib data are quite interesting because of the continued effects despite having stopped it for 14 weeks. Usually, one would expect to see the HbA1c levels climb towards baseline when the medication is stopped, but with Icovamenib, the HbA1c levels decreased, which is quite intriguing and unprecedented." Julio Rosenstock, MD., Director Velocity Clinical Research at Medical City Dallas and Clinical Professor of Medicine, Univ. of Texas Southwestern Medical Center

Industry Context

This announcement positions Biomea Fusion as a significant player in the rapidly evolving diabetes and obesity treatment landscape. The development of BMF-650, a next-generation oral GLP-1 RA, directly competes within the highly lucrative and expanding GLP-1 market, aiming for a 'best-in-class' profile with improved tolerability and patient-friendly titration. Concurrently, Icovamenib's focus on restoring beta-cell function addresses a critical unmet need in Type 2 Diabetes by targeting a root cause, differentiating it from existing chronic therapies that primarily manage symptoms. This dual approach allows Biomea to target both the broad obesity market and the specific, high-need insulin-deficient diabetes population, potentially expanding its reach across broader T2D populations and offering synergistic treatment options.

Comparison to Industry Standards

• BMF-650's preclinical weight reduction (12-15% over 4 weeks) and food intake suppression in obese cynomolgus monkeys compared favorably to published preclinical data for other leading oral GLP-1 RA candidates like Orforglipron (Eli Lilly) and CT-996 (Roche/Carmot Therapeutics).
• BMF-650 demonstrated 2 to 3-fold greater oral bioavailability in preclinical studies compared to orforglipron.
• Icovamenib's 1.5% placebo-adjusted HbA1c reduction at Week 26 in severe insulin-deficient diabetes patients compares favorably to the HbA1c reductions observed with currently approved chronic dosing therapies such as Ozempic (injectable GLP-1 agonist, -1.2% to -1.5% at Week 30), Mounjaro (injectable GLP-1/GIP agonist, -1.6% to -1.7% at Week 40), Jardiance (oral SGLT2 inhibitor, -0.7% to -0.9% at Week 24), and Januvia (oral DPP4 inhibitor, -0.8% at Week 24). It is important to note these are cross-study comparisons and not head-to-head trials.
• Unlike current chronic diabetes treatments that show a rebound in glucose levels after discontinuation (e.g., tirzepatide), Icovamenib demonstrated sustained HbA1c reduction and increased C-peptide levels well beyond the 12-week treatment period, suggesting a unique, potentially disease-modifying effect not seen with other antihyperglycemic agents.

Stakeholder Impact

• **Shareholders:** Positive preclinical and early clinical data for key drug candidates could lead to increased investor confidence and potential share price appreciation, though current financial losses indicate ongoing capital needs.
• **Patients (Type 2 Diabetes & Obesity):** The development of Icovamenib offers potential for a disease-modifying treatment that could restore beta-cell function and reduce reliance on chronic medication. BMF-650 offers a new, potentially best-in-class oral GLP-1 RA option for weight loss and glycemic control.
• **Healthcare Providers:** New treatment options, especially those addressing root causes or offering improved patient-friendly profiles, could significantly impact treatment paradigms for diabetes and obesity.
• **Competitors:** Biomea Fusion's advancements, particularly in the GLP-1 RA and menin inhibitor spaces, could intensify competition in the diabetes and obesity markets, potentially influencing R&D strategies and market share.

Next Steps

• Submit Investigational New Drug (IND) application for BMF-650 in the second half of 2025.
• Initiate Phase I study of BMF-650 in obese, healthy volunteers in the second half of 2025.
• Present a full set of preclinical data for BMF-650 at an upcoming medical conference.
• Release 52-week follow-up data from COVALENT-111 and COVALENT-112 studies in the second half of 2025.
• Provide an FDA Type C Meeting Update for the Menin Program in the second half of 2025.
• Plan initiation of Phase IIb study (COVALENT-211) in severe insulin-deficient patients in the second half of 2025.
• Plan initiation of Phase II study (COVALENT-212) in patients uncontrolled on GLP-1 based therapies in the second half of 2025.

Key Dates

Recommendation

Keywords

Diabetes, Obesity, GLP-1 RA, Menin Inhibitor, BMF-650, Icovamenib, Preclinical Data, Clinical Trials, Type 2 Diabetes, Weight Loss, HbA1c, C-peptide, Beta-cell function, Drug Development, Biotechnology, Pharmaceuticals, SEC Filing, 8-K